RESUMEN
Objective: To investigate the application of single-molecule PCR (SM-PCR) in the detection of plasma ctDNA for the treat-ment of patients with advanced lung adenocarcinoma. Methods: In total, 30 patients diagnosed with advanced lung adenocarcinoma were enrolled between June 2017 and May 2018. ctDNA fragments of the target genes (EGFR, KRAS, BRAF, ALK, HER2, and TP53) from the blood samples were enriched by SM-PCR, and DNA libraries were prepared. Finally, a high-throughput sequencing was performed. The EGFR detection of tumor tissue samples was performed using real-time fluorescence PCR based on the amplification refractory mutation system (ARMS) and consistency in the results of EGFR mutation detection in the plasma and tissue was compared. Results:The results of both the methods were consistent (Kappa=0.867, P<0.001). The McNemar's test also indicated that the results are not statistically different (P=0.500). Conclusions: SM-PCR can be used for the detection of plasma EGFR mutations. The target detection sites are more comprehensive and multiple mutations can be detected at the same time. Results of the analysis are more precise and can be absolutely quantified.
RESUMEN
Thymic carcinoma (TC) is a rare malignant tumor of the mediastinum with occult onset, rapid development, and poor prognosis. Surgery is the main treatment for early TC, but the majority of patients are diagnosed at Masaoka-Koga stage III or IV with local invasion or distant metastasis. Platinum and anthracyclines are currently considered key components of first-line chemotherapy for advanced TC; however, there are no standard treatment plans for patients who are refractory to first-line and further chemotherapy. The clinical effect is also unsatisfactory. Apatinib has been successfully applied as third-line treatment for advanced gastric cancer and has shown high efficacy in the treatment of various cancers, such as lung, liver, and colorectal cancers. Herein we report a case of advanced thymic squamous cell carcinoma harboring EGFR exon 20 insertion in which apatinib was administered after multi-line chemotherapy and radiotherapy and a partial response was achieved after five months of treatment. To date, a five month overall response and 10 months of progression-free survival have been achieved. Adverse reactions can be controlled and the patient's quality of life has improved. Apatinib provides a new option for clinicians to treat patients with advanced TC.
Asunto(s)
Carcinoma de Células Escamosas/tratamiento farmacológico , Piridinas/administración & dosificación , Neoplasias del Timo/tratamiento farmacológico , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/patología , Supervivencia sin Enfermedad , Receptores ErbB/genética , Exones/genética , Humanos , Masculino , Persona de Mediana Edad , Mutagénesis Insercional , Estadificación de Neoplasias , Supervivencia sin Progresión , Piridinas/efectos adversos , Calidad de Vida , Neoplasias del Timo/genética , Neoplasias del Timo/patologíaRESUMEN
In recent years, the number of advanced non-small cell lung cancer (NSCLC) patients has gradually increased, and the treatment methods have also been significantly increased. However, there are no standard treatment plans at home and abroad for third-line and above patients who are refractory to targeted therapy epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) or chemotherapy. The clinical treatment effect is also not satisfactory. Anlotinib is a novel TKI targeting the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit. ALTER0303 trail, phase III study has demonstrated that Anlotinib significantly prolonged overall survival (OS) and progression-free survival (PFS) in advanced NSCLC patients as 3rd line treatment.Here we report a case of advanced lung adenocarcinoma harboring KRAS mutation treated with Anlotinib. .
Asunto(s)
Anciano , Humanos , Masculino , Adenocarcinoma , Quimioterapia , Genética , Patología , Adenocarcinoma del Pulmón , Antineoplásicos , Usos Terapéuticos , Indoles , Usos Terapéuticos , Neoplasias Pulmonares , Quimioterapia , Genética , Patología , Mutación , Proteínas Proto-Oncogénicas p21(ras) , Genética , Metabolismo , Quinolinas , Usos TerapéuticosRESUMEN
Objective To systematically review the correlation between birth weight and blood pressure of child and adolescent, and provide a theoretical basis for the etiologic research and the prevention for hypertension of child and adolescent.Methods Comprehensive electronic searches of Chinese Web of Knowledge (CNKI), Wang Fang, Wei Pu (VIP), PubMed and Web of Science were conducted to identify any study reporting the correlation of birth weight and blood pressure of child and adolescent.SPSS 13.0 software was used to convert the data.Meta-analysis was conducted with STATA 12.0 software.Results Thirty four researches were included in this study.The results of meta-analysis showed that low birth weight children or adolescents had a higher risk of hypertension with a significant difference compared to the group which birth weight greater than 2 500 g (OR =1.20;95％ CI:1.09-1.33;P ＜ 0.01).Its systolic blood pressure and diastolic blood pressure was on the high side.In addition, it showed that no significant differences were found between hypertension and high birth weight (OR =1.03;95％ CI:0.89-1.18;P ＞ 0.05).But its systolic blood pressure and diastolic blood pressure was on the high side too.Conclusions Abnormal birth weight is probably a risk factor of child and adolescent high blood pressure.Low birth weight has greater influence on blood pressure of children and adolescents.It can be detected early to prevent abnormal birth weight and child hypertension.
RESUMEN
To obtain chemical constituent information of rat plasma after oral administration of Huang-Lian-Jie-Du Decoction (HLJDD), a LC-FT-ICR-MS method has been established, and both positive and negative ions scan modes were include in the analysis. By comparing their retention time, high resolution mass data of HLJDD extracts, blank plasma and dosed plasma, 38 constituents, including 22 prototype compounds and 16 metabolites, were detected in rat plasma after oral administration of HLJDD. In the 22 prototype compounds, 16 constituents were determined unambiguously by comparing with references. In the analysis of metabolites, phase II reactions like glucuronidation and sulfation were the major biotransformation pathways of HLJDD. M11 was observed as the only phase I metabolite in present experiment. The results will be beneficial for the further pharmacokinetics and pharmacological evaluations of HLJDD.
Asunto(s)
Animales , Masculino , Ratas , Administración Oral , Alcaloides , Sangre , Biotransformación , Cromatografía Líquida de Alta Presión , Combinación de Medicamentos , Medicamentos Herbarios Chinos , Metabolismo , Flavonoides , Sangre , Iridoides , Sangre , Plantas Medicinales , Química , Ratas Sprague-Dawley , Espectrometría de Masa por Ionización de Electrospray , Espectrometría de Masas en TándemRESUMEN
To obtain chemical constituent information of rat plasma after oral administration of Huang-Lian-Jie-Du Decoction (HLJDD), a LC-FT-ICR-MS method has been established, and both positive and negative ions scan modes were include in the analysis. By comparing their retention time, high resolution mass data of HLJDD extracts, blank plasma and dosed plasma, 38 constituents, including 22 prototype compounds and 16 metabolites, were detected in rat plasma after oral administration of HLJDD. In the 22 prototype compounds, 16 constituents were determined unambiguously by comparing with references. In the analysis of metabolites, phase II reactions like glucuronidation and sulfation were the major biotransformation pathways of HLJDD. M11 was observed as the only phase I metabolite in present experiment. The results will be beneficial for the further pharmacokinetics and pharmacological evaluations of HLJDD.